|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Validating the APUC-6 Signature in mHSPC from the ECOG-ACRIN E3805 CHAARTED Trial
|
|
Xiaolei Shi, MD
|
| Xiaolei Shi discusses biomarker findings from the CHAARTED trial, revealing how six androgen production uptake and conversion genes (APUC-6) combined with AR expression may guide treatment intensification decisions in metastatic hormone-sensitive prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting |
|
|
|
|
| Germline Indicators of Radiation Therapy Response in Both Aggressive and Non-Aggressive Prostate Cancer Subtypes |
| David Miyamoto, MD |
| This multi-institutional study evaluated germline mutations in prostate cancer patients treated with radiation therapy, comparing aggressive cribriform/intraductal carcinoma subtypes with non-aggressive controls. While these aggressive subtypes had worse biochemical recurrence-free survival overall, they were strongly enriched for DNA damage repair mutations, which were paradoxically associated with improved outcomes after radiotherapy. |
|
|
|
|
|
| Prognostic Value of Quantitative Imaging Metrics Obtained in Routine Clinical Practice in a Cohort of Patients Treated with PSMA-RLT |
| John Floberg, MD, PhD |
| John Floberg presented findings showing that SUVmean from PSMA PET imaging, when calculated automatically with the TRAQinformIQ tool, is a strong prognostic marker for response to PSMA radioligand therapy. In a cohort of 50 patients, higher SUVmean (≥8) was significantly associated with greater PSA response rates and longer progression-free survival, while other imaging metrics (percent PSMA-negative disease and PSMA-avid volume) were not predictive. |
|
|
|
|
|
| Validation of a Prognostic Multimodal Artificial Intelligence Model in Asian Prostate Cancer Patients from Singapore
|
| Melvin Lee Kiang Chua, MBBS, FRCR, PhD
|
| Melvin Chua validated the ArteraAI multimodal prognostic model in an Asian prostate cancer cohort from Singapore, demonstrating that AI-derived biopsy and clinical data scores were independently associated with risk of distant metastasis. The model reclassified risk across NCCN groups, including down-classifying some high/very-high risk patients, and showed strong prognostic value after long-term follow-up.
|
|
|
|
|
|
|
|
|
|
|
| Discordance of Adverse Molecular Features between the 22-Gene Genomic Classifier Score, Histologic Grade, and NCCN Risk Groups: Analysis of Over 200,000 Patients |
| Angela Jia, MD, PhD |
| Angela Jia presented an analysis of over 200,000 patients showing significant discordance between Decipher genomic classifier scores, histologic grade, and NCCN risk groups. Adverse molecular features (p53 mutations, PTEN loss, low AR activity) were most strongly correlated with genomic classifier scores rather than grade or NCCN grouping, with nearly a 20-fold higher prevalence of adverse features in very high versus low genomic classifier categories. |
|
|
|
|
|
| Post-Treatment ctDNA Alterations as Predictors of Response to 177Lu-PSMA-617 in mCRPC |
| Opeoluwa Akerele, MD, PhD |
| Opeoluwa Akerele presented a study showing that ctDNA alterations can help predict response to 177Lu-PSMA-617 in mCRPC. In 34 patients, responders were less likely to have copy number amplifications or AR/CCNE1 mutations, while ATM mutations correlated with improved response. These findings suggest ctDNA could serve as a predictive biomarker for treatment resistance or sensitivity, but validation in larger prospective studies is needed. |
|
|
|
|
|
| Evaluating Molecular Response Using 68Ga-PSMA-PET/CT in Prostate Cancer Patients with Pelvic Lymph Node Metastasis Undergoing Definitive Radiotherapy: Clinical Significance and Implications |
| Cem Onal, MD |
| H. Cem Onal presented a retrospective study of 107 prostate cancer patients with pelvic lymph node metastases, showing that molecular response on 68Ga-PSMA-PET/CT after definitive radiotherapy plus ADT strongly predicts outcomes. Patients achieving complete metabolic response in primary tumors or lymph nodes had significantly higher 5-year metastasis-free, progression-free, and cancer-specific survival. |
|
|
|
|
|
|
|
|
|
|
